Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 3
2003 5
2004 2
2005 1
2007 1
2008 1
2009 1
2010 1
2012 5
2013 9
2014 7
2015 5
2016 9
2017 9
2018 12
2019 11
2020 23
2021 27
2022 32
2023 26
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
An expert consensus framework for asthma remission as a treatment goal.
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS. Menzies-Gow A, et al. J Allergy Clin Immunol. 2020 Mar;145(3):757-765. doi: 10.1016/j.jaci.2019.12.006. Epub 2019 Dec 19. J Allergy Clin Immunol. 2020. PMID: 31866436 Free article. Review.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Menzies-Gow A, et al. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. N Engl J Med. 2021. PMID: 33979488 Clinical Trial.
Targeting TSLP in Asthma.
Parnes JR, Molfino NA, Colice G, Martin U, Corren J, Menzies-Gow A. Parnes JR, et al. Among authors: menzies gow a. J Asthma Allergy. 2022 Jun 3;15:749-765. doi: 10.2147/JAA.S275039. eCollection 2022. J Asthma Allergy. 2022. PMID: 35685846 Free PMC article. Review.
FeNO in Asthma.
Loewenthal L, Menzies-Gow A. Loewenthal L, et al. Among authors: menzies gow a. Semin Respir Crit Care Med. 2022 Oct;43(5):635-645. doi: 10.1055/s-0042-1743290. Epub 2022 Mar 4. Semin Respir Crit Care Med. 2022. PMID: 35253144 Free article.
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å, Mo M, Garcia Gil E. Menzies-Gow A, et al. Respir Res. 2020 Oct 13;21(1):266. doi: 10.1186/s12931-020-01526-6. Respir Res. 2020. PMID: 33050934 Free PMC article. Clinical Trial.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Among authors: menzies gow a. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Among authors: menzies gow a. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
174 results